Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RADX

Radiopharm Theranostics Ltd ADR

Apr 30 • 10:17AM ET

4.33

-0.02 -0.46 %

Healthcare • Biotechnology • Australia • Micro • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.94	Insider Own	-	Shs Outstand	11.81M	Perf Week	-4.31%
Market Cap	51.14M	Forward P/E	-	EPS next Y	-3.07	Insider Trans	-	Shs Float	-	Perf Month	0.70%
Enterprise Value	26.89M	PEG	-	EPS next Q	-2.09	Inst Own	5.95%	Short Float	-	Perf Quarter	-13.05%
Income	-29.07M	P/S	21.85	EPS this Y	10.55%	Inst Trans	53.46%	Short Ratio	0.25	Perf Half Y	-17.84%
Sales	2.34M	P/B	1.48	EPS next Y	0.66%	ROA	-49.26%	Short Interest	0.04M	Perf YTD	-17.05%
Book/sh	2.92	P/C	2.22	EPS next 5Y	17.17%	ROE	-86.18%	52W High	16.25 -73.35%	Perf Year	10.74%
Cash/sh	1.95	P/FCF	-	EPS past 3/5Y	47.48% -71.93%	ROIC	-84.20%	52W Low	3.62 19.61%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-56.87%	Volatility	5.28% 4.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	11.49	EPS Y/Y TTM	76.04%	Oper. Margin	-1501.80%	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.01	Sales Y/Y TTM	110.08%	Profit Margin	-1245.09%	RSI (14)	41.07	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.01	EPS Q/Q	26.04%	SMA20	-4.59%	Beta	1.11	Target Price	17.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-0.73%	SMA50	-7.15%	Rel Volume	0.05	Prev Close	4.35
Employees	-	LT Debt/Eq	0.00	Earnings	Feb 27 BMO	SMA200	-15.46%	Avg Volume	162.28K	Price	4.33
IPO	Dec 05, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-49.01% 48.59%	Trades		Volume	1,759	Change	-0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-25	Initiated	B. Riley Securities	Buy	$15

Apr-23-26 07:00AM	Radiopharm Theranostics Reports Business Update (GlobeNewswire)
Apr-20-26 07:00AM	Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 (GlobeNewswire)
Apr-16-26 07:00AM	Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases (GlobeNewswire)
Apr-08-26 07:00AM	Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial (GlobeNewswire)
Apr-07-26 07:00AM	Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. (GlobeNewswire)
07:00AM	Loading…
Mar-27-26 07:00AM	Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer (GlobeNewswire)
Mar-26-26 07:20PM	Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial (Proactive)
07:20PM	Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial (Proactive)
Mar-24-26 07:00AM	Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases (GlobeNewswire) -10.78%
Feb-24-26 07:30AM	Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) (GlobeNewswire)
Jan-28-26 07:00AM	Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates (GlobeNewswire)
Jan-12-26 07:00AM	RAD Increases Ownership in Radiopharm Ventures to 87.5% (GlobeNewswire)
Dec-15-25 12:35PM	Radiopharm (RADX) Sees Slight Pessimism From Analysts (Insider Monkey) +149.53%
07:00AM	Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases (GlobeNewswire)
Nov-18-25 08:30AM	Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer (GlobeNewswire)
08:00AM	Loading…
Nov-17-25 08:00AM	Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases (GlobeNewswire)
Nov-12-25 08:30AM	Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 (GlobeNewswire)
Oct-20-25 08:00AM	Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs (GlobeNewswire) -19.83%
07:30AM	Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan (GlobeNewswire)
Oct-02-25 08:15AM	Radiopharm receives DSMC recommendation to advance Phase 1 HEAT trial (TipRanks) +5.57%
Oct-01-25 08:00AM	Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial (GlobeNewswire)
Aug-17-25 01:52AM	Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01) (Insider Monkey)
Jul-29-25 07:30AM	Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update (GlobeNewswire)
Jul-28-25 08:00AM	Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) (GlobeNewswire)
Jul-22-25 08:00AM	Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board (GlobeNewswire)
Jun-24-25 08:00AM	Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹6¹Tb-KLK3-mAb Phase I Clinical Trial in Australia (GlobeNewswire) +5.69%
Jun-11-25 08:00AM	Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases (GlobeNewswire) -5.84%
Jun-04-25 08:00AM	Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors (GlobeNewswire)
Jun-02-25 08:00AM	Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake (GlobeNewswire) +11.16%
May-19-25 08:00AM	ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 (GlobeNewswire)
08:00AM	Loading…
May-12-25 08:00AM	Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) (GlobeNewswire)
May-07-25 08:00AM	Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference (GlobeNewswire)
Apr-28-25 08:00AM	Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis (GlobeNewswire)
Mar-27-25 03:13PM	Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting (SeekingAlpha)
Mar-17-25 08:56AM	New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution (GlobeNewswire) +6.90%
Feb-10-25 08:00AM	New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases (GlobeNewswire)
Jan-10-25 08:00AM	Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement (GlobeNewswire) +32.75%
Dec-30-24 08:00AM	Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia (GlobeNewswire)
Dec-20-24 08:00AM	RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial (GlobeNewswire)
Nov-27-24 08:00AM	Radiopharm Achieves Nasdaq Listing of American Depositary Shares (GlobeNewswire)

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RADX

Radiopharm Theranostics Ltd ADR

Upgrade your Finviz experience